Art. -Nr.: HY-167237

Calactin

Calactin is a glycoside that can be isolated from Asclepias curassavica L.. Calactin activates caspase-3, caspase-8, caspase-9, and phosphorylates ERK. Calactin induces DNA damage, apoptosis, PARP cleavage, G2/M phase cell cycle arrest, shifts Bax/Bcl-2 expression, and shows anti-proliferation effects in leukemia cells. Calactin can be used for the research of leukemia.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

CAS. Nr.: 20304-47-6
Formel: C₂₉H₄₀O₉
Molecular Weight:532.63

Speicherung:

Please store the product under the recommended conditions in the Certificate of Analysis.

Calactin Chemical Structure

CAS. Nr.: 20304-47-6

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
Chemical Information
Reinheit & Dokumentation
Verweise
Calculators
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target^[1]

Caspase-3

Caspase-8

Caspase-9

CDK1/cyclinB1

Bcl-2

Bax

Alle Caspase Isoform-spezifische Produkte anzeigen :

Alle CDK Isoform-spezifische Produkte anzeigen :

Alle PARP Isoform-spezifische Produkte anzeigen :

Alle Bcl-2 Family Isoform-spezifische Produkte anzeigen :

Alle ERK Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	0.0029 μg/mL Compound: 4	Cytotoxicity against human A549 cells after 3 days by MTT assay Cytotoxicity against human A549 cells after 3 days by MTT assay	[PMID: 16252914]
A549	IC₅₀	0.02 μM Compound: 8	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 19555122]
BC	IC₅₀	2.07 × 10^-5M Compound: 4	Cytotoxicity against human BC cells by SRB assay Cytotoxicity against human BC cells by SRB assay	[PMID: 16933890]
BXPC-3	IC₅₀	0.08 μM Compound: 8	Antiproliferative activity against human BxPC3 cells after 72 hrs by MTT assay Antiproliferative activity against human BxPC3 cells after 72 hrs by MTT assay	[PMID: 19555122]
Calu-1	IC₅₀	0.5 μM Compound: 21	Antiproliferative activity against human Calu1 cells after 72 hrs by MTT assay Antiproliferative activity against human Calu1 cells after 72 hrs by MTT assay	[PMID: 30629433]
HeLa	IC₅₀	0.2 μM Compound: 21	Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay	[PMID: 30629433]
HepG2	IC₅₀	0.02 μg/mL Compound: 4	Cytotoxicity against human HepG2 cells after 3 days by MTT assay Cytotoxicity against human HepG2 cells after 3 days by MTT assay	[PMID: 16252914]
KB	IC₅₀	4.13 × 10^-5M Compound: 4	Cytotoxicity against human KB cells by SRB assay Cytotoxicity against human KB cells by SRB assay	[PMID: 16933890]
LoVo	IC₅₀	0.05 μM Compound: 8	Antiproliferative activity against human LoVo cells after 72 hrs by MTT assay Antiproliferative activity against human LoVo cells after 72 hrs by MTT assay	[PMID: 19555122]
MCF7	IC₅₀	0.01 μg/mL Compound: 4	Cytotoxicity against human MCF7 cells after 3 days by MTT assay Cytotoxicity against human MCF7 cells after 3 days by MTT assay	[PMID: 16252914]
MCF7	IC₅₀	0.04 μM Compound: 8	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 19555122]
MCF7	IC₅₀	0.2 μM Compound: 21	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 30629433]
MDA-MB-231	IC₅₀	0.03 μg/mL Compound: 4	Cytotoxicity against human MDA-MB-231 cells after 3 days by MTT assay Cytotoxicity against human MDA-MB-231 cells after 3 days by MTT assay	[PMID: 16252914]
NCI-H187	IC₅₀	3.45 × 10^-4M Compound: 4	Cytotoxicity against human NCI-H187 cells by SRB assay Cytotoxicity against human NCI-H187 cells by SRB assay	[PMID: 16933890]
PC-3	IC₅₀	0.02 μM Compound: 8	Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay	[PMID: 19555122]
PC-3	IC₅₀	3.7 μM Compound: 21	Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay	[PMID: 30629433]
U-251	IC₅₀	0.9 μM Compound: 21	Antiproliferative activity against human U251MG cells after 72 hrs by MTT assay Antiproliferative activity against human U251MG cells after 72 hrs by MTT assay	[PMID: 30629433]
U-373MG ATCC	IC₅₀	0.2 μM Compound: 8	Antiproliferative activity against human U373 cells after 72 hrs by MTT assay Antiproliferative activity against human U373 cells after 72 hrs by MTT assay	[PMID: 19555122]

In Vitro

Calactin (0.065-1 μM; 0-24 h) exhibits dose-dependent and time-dependent cytotoxicity against human leukemia K562 and Molt-4 cells^[1].
Calactin (0.15 μM; 0-24 h) induces G₂/M phase cell cycle arrest in human leukemia K562 and Molt-4 cells by reducing the expression of Cyclin B1, Cdk1, and Cdc25C^[1].
Calactin (0.15 μM; 0-24 h) induces DNA damage in human leukemia K562 and Molt-4 cells^[1].
Calactin (0.15 μM; 0-24 h) induces apoptosis in human leukemia K562 and Molt-4 cells, and this apoptosis proceeds independently of caspase-3 activity^[1].
Calactin (0.15 μM; 0-24 h) induces apoptosis in human leukemia K562 and Molt-4 cells through both intrinsic and extrinsic apoptotic pathways^[1].
Calactin (0.15 μM; 12 h) upregulates c-Fos mRNA expression in K562 and Molt-4 cells via the ERK signaling pathway^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

human leukemia K562 and Molt-4 cells
Concentration:

0.065, 0.125, 0.15, 0.25, 0.5, 1 μM
Incubation Time:

0, 6, 12, 24 h
Result:

Reduced cell viability in a dose-dependent and time-dependent manner.
Exhibited a LD₅₀of 0.161 μM for K562 cells after 12 h treatment.
Exhibited a LD₅₀of 0.142 μM for Molt-4 cells after 12 h treatment.
Caused progressively decreased cell viability relative to untreated controls when used at 0.15 μM for 6, 12, 18, and 24 h.

Cell Cycle Analysis^[1]

Cell Line:

human leukemia K562 and Molt-4 cells
Concentration:

0.15 μM
Incubation Time:

0, 6, 12, 24 h
Result:

Induced a significant increase in the percentage of K562 cells arrested at the G₂/M phase, from 12.8% at 0 h to 34.4% at 24 h.
Reduced the expression levels of Cyclin B1, Cdk1, and Cdc25C in both cell lines over the 24 h treatment period.

Western Blot Analysis^[1]

Cell Line:

human leukemia K562 and Molt-4 cells
Concentration:

0.15 μM
Incubation Time:

0, 6, 12, 24 h
Result:

Increased phosphorylation levels of Chk2 and H2AX in a time-dependent manner.
Showed no change in total Chk2 or H2AX protein expression.

Apoptosis Analysis^[1]

Cell Line:

human leukemia K562 and Molt-4 cells
Concentration:

0.15 μM
Incubation Time:

0, 6, 12, 24 h
Result:

Caused a significant increase in apoptotic cells after treatment.
Did not block calactin-induced phosphatidylserine exposure when cells were pretreated with Z-DEVD-FMK, indicating no reduction in apoptotic cell levels.

Western Blot Analysis^[1]

Cell Line:

human leukemia K562 and Molt-4 cells
Concentration:

0.15 μM
Incubation Time:

0, 6, 12, 24 h
Result:

Induced PARP cleavage in both cell lines over the 24 h treatment period.
Increased levels of active caspase-3, caspase-8, caspase-9, and Bax in both cell lines over the 24 h treatment period.
Decreased levels of procaspase-3, procaspase-8, procaspase-9, and Bcl-2 in both cell lines over the 24 h treatment period.
Increased phosphorylation levels of ERK and Elk-1 in a time-dependent manner, with no change in total ERK or Elk-1 protein expression.

Chemical Information

CAS. Nr. 20304-47-6
Molecular Weight 532.63
Formel C₂₉H₄₀O₉
SMILES

C(=O)[C@@]12[C@@]3([C@]([C@]4(O)[C@](C)(CC3)[C@H](CC4)C5=CC(=O)OC5)(CC[C@]1(C[C@@]6([C@@](C2)(O[C@]7(O)[C@](O6)(O[C@H](C)C[C@H]7O)[H])[H])[H])[H])[H])[H]
Structure Classification
- Terpenoids
- Triterpenes
Initial Source
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

Please store the product under the recommended conditions in the Certificate of Analysis.

Reinheit & Dokumentation

Handling Instructions (2659 KB)

Verweise

[1]. Lee CC, et al. The small molecule calactin induces DNA damage and apoptosis in human leukemia cells. Eur J Cancer Prev. 2012;21(5):467-473. [Content Brief]

Calculators

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Calactin

Alle Caspase Isoform-spezifische Produkte anzeigen

Alle CDK Isoform-spezifische Produkte anzeigen

Alle PARP Isoform-spezifische Produkte anzeigen

Alle Bcl-2 Family Isoform-spezifische Produkte anzeigen

Alle ERK Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Reinheit & Dokumentation

Verweise

Calculators

Help & FAQs

Calactin Related Classifications

HY-167237 Related Classifications